Insmed Inc (INSM)
57.00
+1.06
(+1.89%)
USD |
NASDAQ |
Jun 04, 16:00
57.02
+0.02
(+0.03%)
After-Hours: 20:00
Insmed Research and Development Expense (TTM): 564.23M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 564.23M |
| December 31, 2023 | 571.01M |
| September 30, 2023 | 558.74M |
| June 30, 2023 | 549.47M |
| March 31, 2023 | 441.03M |
| December 31, 2022 | 397.52M |
| September 30, 2022 | 349.11M |
| June 30, 2022 | 319.58M |
| March 31, 2022 | 295.71M |
| December 31, 2021 | 272.74M |
| September 30, 2021 | 264.21M |
| June 30, 2021 | 235.27M |
| March 31, 2021 | 206.36M |
| December 31, 2020 | 181.16M |
| September 30, 2020 | 145.97M |
| June 30, 2020 | 138.90M |
| March 31, 2020 | 136.69M |
| December 31, 2019 | 131.71M |
| September 30, 2019 | 139.01M |
| June 30, 2019 | 144.20M |
| March 31, 2019 | 146.39M |
| December 31, 2018 | 145.28M |
| September 30, 2018 | 139.31M |
| June 30, 2018 | 126.44M |
| March 31, 2018 | 117.59M |
| Date | Value |
|---|---|
| December 31, 2017 | 109.75M |
| September 30, 2017 | 130.67M |
| June 30, 2017 | 127.43M |
| March 31, 2017 | 124.43M |
| December 31, 2016 | 122.72M |
| September 30, 2016 | 87.50M |
| June 30, 2016 | 83.28M |
| March 31, 2016 | 77.66M |
| December 31, 2015 | 74.28M |
| September 30, 2015 | 69.43M |
| June 30, 2015 | 65.41M |
| March 31, 2015 | 62.10M |
| December 31, 2014 | 56.29M |
| September 30, 2014 | 51.12M |
| June 30, 2014 | 48.01M |
| March 31, 2014 | 45.30M |
| December 31, 2013 | 44.28M |
| September 30, 2013 | 46.24M |
| June 30, 2013 | 39.86M |
| March 31, 2013 | 35.38M |
| December 31, 2012 | 29.78M |
| September 30, 2012 | 25.41M |
| June 30, 2012 | 26.64M |
| March 31, 2012 | 27.60M |
| December 31, 2011 | 28.62M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
131.71M
Minimum
Dec 2019
571.01M
Maximum
Dec 2023
302.13M
Average
268.48M
Median
Research and Development Expense (TTM) Benchmarks
| Cytokinetics Inc | -- |
| Amicus Therapeutics Inc | 139.21M |
| Predictive Oncology Inc | -- |
| Agios Pharmaceuticals Inc | 296.84M |
| Arcutis Biotherapeutics Inc | 98.37M |